A b s t r a c t The effect of using a 30 % cutoff for the proportion of HER2+ cells on the interobserver variability in the interpretation of HER2 immunohistochemical results was evaluated. Immunostained sections from 96 cases of breast carcinoma were reviewed by 10 pathologists and scored as positive (3+) when uniform strong membranous staining was identified in at least 10 % of tumor cells; the actual percentage of cells with such staining was also estimated. The agreement rates and the κ values using a 30 % cutoff were compared with those using a 10 % cutoff. These proved to be higher in 62 % and 66 % of measurements, respectively, with average interobserver rates and κ values of 72 % and 0.54 using the 30 % cutoff and 70 % and 0.49 usin
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixe...
IntroductionBiomarkers, such as Estrogen Receptor, are used to determine therapy and prognosis in br...
Abstract. The HER2 gene is amplified and overexpressed in 25–30 % of breast carcinomas. Assessment o...
In immunochemical assays of specific cell constituents in cytosols from tumors, the relationship bet...
AIMS: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a...
Abstract Background Detection of HER2/neu receptor ov...
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to det...
The HercepTest was approved 20+ years ago as the companion diagnostic test for trastuzumab in human ...
In spite of the large number of studies on technical problems affecting the interlaboratory reproduc...
<p>A: Assignment of the tumor compartment as defined by cytokeratin and DAPI fluorescence in section...
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for...
Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression a...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixe...
IntroductionBiomarkers, such as Estrogen Receptor, are used to determine therapy and prognosis in br...
Abstract. The HER2 gene is amplified and overexpressed in 25–30 % of breast carcinomas. Assessment o...
In immunochemical assays of specific cell constituents in cytosols from tumors, the relationship bet...
AIMS: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a...
Abstract Background Detection of HER2/neu receptor ov...
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to det...
The HercepTest was approved 20+ years ago as the companion diagnostic test for trastuzumab in human ...
In spite of the large number of studies on technical problems affecting the interlaboratory reproduc...
<p>A: Assignment of the tumor compartment as defined by cytokeratin and DAPI fluorescence in section...
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for...
Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression a...
The human epidermal growth factor receptor-2 (HER2) protein has been associated with breast cancer p...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixe...
IntroductionBiomarkers, such as Estrogen Receptor, are used to determine therapy and prognosis in br...